Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang

Questions loom as to whether Allergan's pair of CGRP antagonists will face the liver toxicity issues that previously plagued oral CGRP drugs. The firm is counting on the migraine therapies to help offset revenues lost to generics.